Dr. Simon Widmaier has a biophysics background and a PhD in molecular simulation from the Karlsruhe Institute of Technology. In addition, he has founded multiple successful start-ups within the last 10 years, ranging from social business or industrial simulation software to miniaturized screening solutions for drug discovery and pharma research. Simon joined faCellitate in March 2020 as COO.
Dr. Annamarija Raic joined faCelliate in October 2020 and devotes her years of experience in the field of synthetic biomaterials and stem cell biology to the innovation of new products. During her time as PhD student and Postdoc at the Karlsruhe Institute of Technology and Leibniz University of Hannover she focused on the development of in vitro models for bone marrow diseases.
Tanja Schollmeier holds a master’s degree in marine biology from the University of Alaska Fairbanks with a focus on Arctic ecology. She has extensive experience in biomarker analysis with emphasis on microalgae. With her additional background in communication, Tanja joined faCellitate in June 2021 as Customer Experience Manager. At faCellitate, Tanja is coordinating marketing campaigns and customer interactions.
Tamandeep Singh Dhawan joined faCellitate in March 2021 as a digital marketing analyst and holds a Masters's degree in International Marketing from Gisma business school, Berlin and bachelor’s degree in Business economics from the university of Delhi, India. During his time as a bachelor’s student, he started his startup focusing on Marketing which revolves around affiliate marketing, ATL BTL campaigning and brand activation. At facellitate Tamandeep is responsible for the smooth functioning of digital marketing campaigns and improving the marketing strategies.
Dr. Valentina Fermi has a PhD in immuno-oncology from Heidelberg University. She joined faCellitate in Mai 2022 to support the R&D team with her experience in primary human cell culture and in vitro investigation of cancer immunotherapies. During her time as PhD student and Postdoc at Heidelberg University Hospital, she focused on the development of ex vivo tumour models for high-throughput drug screening.